keyword
https://read.qxmd.com/read/38018048/-analysis-of-etiology-and-complications-in-children-with-stage-5-chronic-kidney-disease
#61
JOURNAL ARTICLE
C Zhong, Y L Chen, X X Yu, Q Yang, Y Q Shi, L W Tan, A S Wang, D Q Wu, G F Zhang, H P Yang, Q Li, M Wang
Objective: To investigate the etiology, complications, and prognostic factors of stage 5 chronic kidney disease (CKD5) in children. Methods: A case series study was conducted to retrospectively analyze the general situation, clinical manifestations, laboratory tests, genetic testing, and follow-up data (until October 2022) of 174 children with CKD5 who were diagnosed and hospitalized at the Children's Hospital of Chongqing Medical University from April 2012 to April 2021. The characteristics of complications in the children were compared based on age, gender, and etiology...
December 2, 2023: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://read.qxmd.com/read/38008090/de-novo-atypical-hemolytic-uremic-syndrome-associated-with-c3-gene-mutation-after-kidney-transplantation-a-rare-case-of-life-threatening-diffuse-alveolar-hemorrhage-in-an-adolescent
#62
Ji Yeon Song, Seung Hwan Oh, Younga Kim
INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) disease entity primarily attributed to genetic or acquired abnormalities in the alternative complement pathway. TMA can manifest in kidney transplant (KT) recipients owing to various factors, resulting in diverse clinical presentations. Given its adverse effects on allograft function and patient prognosis, genetic diagnostic approaches for aHUS are essential. Although rarely associated with diffuse alveolar hemorrhage, only a few mild cases have been reported to date...
November 24, 2023: Nephron
https://read.qxmd.com/read/38007827/-renal-replacement-therapy-in-cancer-patients-with-aki
#63
REVIEW
Marco Pozzato, Roberta Fenoglio, Nunziante Caruso, Cecilia Ceruti, Giorgio Amore, Savino Sciascia, Dario Roccatello
Acute renal failure (AKI) is a high-prevalence complication in patients with cancer. The risk of AKI after cancer diagnosis is 18% in the first year, 27% in the fifth year, and 40% of critically ill patients with cancer require renal replacement therapy. The causes of AKI may be pre-renal due to hemodynamic problems, related to the cancer, metabolic complications, and drug or surgical treatment. One must preventively protect renal function by hydration, use of non-nephrotoxic drugs, correction of anemia, prevention of contrast agent-induced AKI (CI-AKI), and adjustment of cancer therapy in patients with CKD...
October 3, 2023: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://read.qxmd.com/read/37985009/evaluation-of-bone-marrow-findings-in-hemodialysis-patients-with-erythropoietin-resistant-anemia
#64
JOURNAL ARTICLE
Mehmet Yilmaz, Volkan Karakuş, Egemen Kaya, Nevruz İlhanlı, Bülent Huddam
INTRODUCTION: Treatment with erythropoietin-stimulating agents (ESAs) is widely used in anemia of chronic kidney disease (CKD). Acquired ESA resistance is an important problem. The aim of this study is to examine the bone marrow findings in hemodialysis patients with ESA-resistant anemia. METHODS: The data of 210 patients with acquired ESA resistance were reviewed retrospectively. The patients were divided into groups according to having diagnosis of dysplasia and hematological disease, and survival analysis was performed...
April 2024: Therapeutic Apheresis and Dialysis
https://read.qxmd.com/read/37975611/effect-of-the-phosphate-binder-sevelamer-carbonate-on-the-bioavailability-of-enarodustat-an-oral-erythropoiesis-stimulating-agent
#65
JOURNAL ARTICLE
Sudhakar M Pai, Hiroyuki Yamada
Enarodustat is an orally available hypoxia-inducible factor-prolyl hydroxylase inhibitor which can correct the erythropoietic capacity and improve anemia in chronic kidney disease. Sevelamer carbonate, a non-calcium-based polymeric resin, is one of the commonly prescribed agents for the management of hyperphosphatemia in patients undergoing hemodialysis. This was an open-label, crossover study in healthy male subjects (N = 12) that evaluated the effect of sevelamer carbonate (2400 mg) on the bioavailability of enarodustat (25 mg) when the 2 drugs were administered together (Treatment B) or when enarodustat was administered 3 hours after (Treatment C) or 1 hour before (Treatment D) sevelamer carbonate compared to enarodustat alone (Treatment A)...
November 17, 2023: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/37969110/efficacy-of-roxadustat-in-maintenance-hemodialysis-patients-with-erythropoietin-hyporesponsive-anemia
#66
JOURNAL ARTICLE
Xiaoshuang Wang, Hezhou Cai, Haifan Xu, Liqun Chen
OBJECTIVE: To investigate the efficacy of roxadustat in hemodialysis patients with erythropoietin (EPO) hypo-responsive anemia. MATERIALS AND METHODS: This retrospective study included 55 hemodialysis patients with erythropoietin hypo-responsive anemia at the First Affiliated Hospital of Chongqing Medical University from January to December 2020. We observed their hemoglobin (Hb) changes, inflammatory factors, and adverse reactions before and after 12 weeks of roxadustat treatment...
January 2024: Clinical Nephrology
https://read.qxmd.com/read/37960311/association-of-estimated-total-body-iron-with-all-cause-mortality-in-japanese-hemodialysis-patients-the-miyazaki-dialysis-cohort-study
#67
JOURNAL ARTICLE
Tatsunori Toida, Yuji Sato, Hiroyuki Komatsu, Shouichi Fujimoto
Iron deficiency/excess may be associated with worse prognosis in patients undergoing hemodialysis. This study ascertained the association of the estimated total body iron (TBI) with mortality in patients receiving hemodialysis. Multicenter clinical data collected in the Miyazaki Dialysis Cohort Study from 943 patients receiving hemodialysis were analyzed after stratification into tertile categories by baseline TBI-estimated as the heme iron plus iron storage from ferritin levels. The primary outcome was a 5-year all-cause mortality; hazard ratios of the TBI-all-cause mortality association were estimated using Cox models adjusted for potential confounders, including clinical characteristics, laboratory, and drug data, wherein patients with high TBI were the reference category...
November 3, 2023: Nutrients
https://read.qxmd.com/read/37935135/proton-pump-inhibitors-and-hyporesponsiveness-to-erythropoiesis-stimulating-agents-in-hemodialysis-patients-results-from-the-japan-dialysis-outcomes-and-practice-patterns-study
#68
JOURNAL ARTICLE
Akio Nakashima, Yoshia Miyawaki, Hirotaka Komaba, Noriaki Kurita, Yoshihiro Onishi, Takashi Yokoo, Masafumi Fukagawa
INTRODUCTION: Hyporesponsiveness to erythropoiesis stimulating agents (ESAs) is important problem in dialysis patients. While proton pump inhibitors (PPIs) may inhibit iron absorption, few studies have examined associations between PPIs and ESA-resistant anemia in hemodialysis patients. This study examined the associations between PPIs and ESA-resistant anemia in hemodialysis patients. METHODS: The present study was a cross-sectional study using repeated 4-month observations, up to eight observations/patient, from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS)...
2024: American Journal of Nephrology
https://read.qxmd.com/read/37927773/a-case-report-of-brash-bradycardia-renal-failure-atrioventricular-av-blockage-shock-and-hyperkalemia-syndrome-with-a-challenging-diagnosis-and-management-dilemma
#69
Muhammad Ghallab, Nicole C Noff, Jasmine Sandhu, Alli El-Ijla, Karim Makhoul, Asad Sahibzada, Most Munira
BRASH syndrome, characterized by bradycardia, renal failure, atrioventricular (AV) blockage, shock, and hyperkalemia, is an emerging clinical entity that challenges healthcare practitioners. This case report presents a unique instance of BRASH syndrome with an atypical presentation in a 56-year-old woman with a past medical history of hypertension, diabetes, and chronic kidney disease. Initial laboratory results revealed severe normocytic anemia, thrombocytopenia, renal dysfunction, acidosis, and hyponatremia, alongside hyperkalemia and hypothyroidism...
October 2023: Curēus
https://read.qxmd.com/read/37900680/case-report-thrombotic-microangiopathy-in-pediatric-multisystem-inflammatory-syndrome-associated-with-covid-19-a-case-series
#70
Hülya Nalçacıoğlu, H Gözde Önal, Burcu Bozkaya Yücel, Demet Tekcan Karali, Emine Erdeniz, Gökçen Öz Tuncer, Özlem Aydoğ
INTRODUCTION: This report provides insight into three distinct pediatric cases exhibiting a nexus between multisystem inflammatory syndrome in children (MIS-C) and thrombotic microangiopathy (TMA) triggered by COVID-19. The aim is to underscore the range of clinical presentations and the essentiality of early interventions. CASE PRESENTATIONS: This report presents three cases aged 10 months, 7 years, and 3 years with persistent fever, diarrhea, nausea, and vomiting...
2023: Frontiers in Pediatrics
https://read.qxmd.com/read/37884647/regular-laboratory-testing-and-patient-survival-among-patients-undergoing-maintenance-hemodialysis-a-korean-nationwide-cohort-study
#71
JOURNAL ARTICLE
Do Hyoung Kim, AJin Cho, Hayne Cho Park, Bo Yeon Kim, Miri Lee, Gui Ok Kim, Jinseog Kim, Young-Ki Lee
Routine laboratory tests are regularly performed in patients undergoing maintenance hemodialysis (HD) to detect anemia, chronic kidney disease-mineral bone disorders, and cardiovascular disease. More frequent laboratory tests may be associated with better outcomes. However, there is little evidence supporting a specific monitoring interval. This study evaluated the impact of regular laboratory testing on mortality in Korean patients undergoing maintenance HD. We used HD quality assessments, and National Health Insurance Service claims data from October to December 2015...
October 26, 2023: Scientific Reports
https://read.qxmd.com/read/37877297/comparative-analysis-of-roxadustat-efficacy-between-maintenance-hemodialysis-and-peritoneal-dialysis-patients
#72
JOURNAL ARTICLE
Liling Zhang, Yan Huang, Defeng Yin, Tingting Zhu, Qi Liu, Ying Li, Linwang Gan
BACKGROUND: This study evaluated the comparative efficacy of roxadustat for renal anemia between patients on maintenance hemodialysis (HD) and peritoneal dialysis (PD). MATERIALS AND METHODS: 93 maintenance dialysis patients who regularly followed up from August 2015 to June 2021 were enrolled. Despite receiving a therapeutic dose ≥ 12,000 U/week of erythropoiesis-stimulating agents (E+SA) in the past 12 weeks, this had not worked very well. Subjects were assigned to the HD group (n = 60) or the PD group (n = 33) based on their dialysis treatment modality...
January 2024: Clinical Nephrology
https://read.qxmd.com/read/37875459/a-phase-3b-multicenter-open-label-single-arm-study-of-roxadustat-within-a-us-dialysis-organization-the-denali-study
#73
MULTICENTER STUDY
John Larkin, Jeffrey Hymes, Marcus L Britton, Yemmie Oluwatosin, Jacqueline Nolen, Lixia Zhu, Arnold Silva
INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in several regions for the treatment of anemia of chronic kidney disease (CKD). DENALI, a phase 3b study, evaluated the efficacy, safety, and feasibility of roxadustat in patients with anemia of CKD receiving in-center or home dialysis. METHODS: Eligible patients received open-label roxadustat, dosed three times weekly for 24 weeks, with an optional extension of ≤1 year...
January 2024: Hemodialysis International
https://read.qxmd.com/read/37861032/clinical-biochemical-and-molecular-features-of-a-cohort-of-8-patients-with-inherited-disorders-of-vitamin-b12-metabolism-in-a-metabolic-reference-center
#74
JOURNAL ARTICLE
Gonçalo Padeira, Sandra Jacinto, Augusto Ribeirinho, Ana Cristina Ferreira
BACKGROUND: Vitamin B12, or cobalamin (Cbl), undergoes a complex series of absorptive and intracellular processing steps before serving as a cofactor for the enzymes methylmalonyl-CoA mutase and methionine synthase. Disorders of intracellular cobalamin metabolism have variable phenotypes and age of onset related to the location of the defect in the metabolic pathway leading to a combined methylmalonic acidemia and homocystinuria (cblC, cblD, cblF and cblJ), Isolated methylmalonic acidemia (cblA, cblB and cblDv2) and isolated homocystinuria (cblDv1, cblE and cblG)...
October 11, 2023: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/37853507/effect-of-vitamin-d-supplementation-on-management-of-anemia-in-hemodialysis-patients-with-vitamin-d-deficiency-a-double-blind-randomized-controlled-trial
#75
JOURNAL ARTICLE
Sameh Mohamed Emarah, Mohamed Abd El Rahman Ahmed, Ghada Mohamed El Kannishy, Ahmed Elsaeed Abdulgalil
INTRODUCTION: Anemia and vitamin D deficiency are common problems among hemodialysis (HD) patients. This study aimed to assess the impact of correction of vitamin D deficiency with vitamin D supplementation on the improvement of anemia in patients with end-stage renal disease (ESRD) on maintenance HD. METHODS: This double-blind, randomized, controlled study included 100 anemic HD patients with vitamin D deficiency who were randomly divided using the closed envelop method into two groups (1:1)...
January 2024: Hemodialysis International
https://read.qxmd.com/read/37845470/abcs-of-hemodiafiltration-prescription-the-pisa-style
#76
REVIEW
Emanuela Mangione, Domenico Giannese, Adamasco Cupisti, Vincenzo Panichi
In end-stage kidney disease patients, hemodiafiltration, a mixed diffusive-convective technique, has shown beneficial effects in terms of improvement of anemia, inflammation, mineral bone disorders, malnutrition and cardiovascular stability. Greater convective volume exchange was also associated with improved overall and cardiovascular survival. However, absolute target threshold volume would be difficult to define and achieve in daily clinical practice, mainly because of differences in patient size. Convective volumes standardized for body surface area would appear to be the simplest approach in clinical practice...
March 2024: Journal of Nephrology
https://read.qxmd.com/read/37843847/roxadustat-treatment-for-erythropoiesis-stimulating-agent-hyporesponsive-anemia-in-maintenance-hemodialysis-patients
#77
JOURNAL ARTICLE
Jie Song, Xiaojun Chen, Linshan Zhou, Weihong Yu, Hong Liu, Fang Yuan
OBJECTIVE: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is a prevalent problem affecting hemodialysis (HD) patients. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. We explored the ability of roxadustat to increase the hemoglobin (Hb) concentration in ESA-hyporesponsive patients undergoing HD and assessed its effect on iron metabolism and inflammation. METHODS: This prospective study included 30 patients with ESA-hyporesponsive anemia who had been undergoing stable dialysis...
October 2023: Journal of International Medical Research
https://read.qxmd.com/read/37837449/respiratory-failure-in-systemic-sclerosis
#78
REVIEW
Joaquim Ivo Vasques Dantas Landim, Andre Silva Franco, Percival Degrava Sampaio-Barros, Renata Miossi, Ana Cristina Medeiros-Ribeiro, Rosa Maria R Pereira, Ana Paula Luppino Assad
Systemic sclerosis (SSc) can lead to dyspnea and respiratory failure through multiple mechanisms, making a precise diagnosis particularly challenging, especially amid the current COVID-19 pandemic. In this report, we present a case involving a 26-year-old female who had previously undiagnosed SSc. She experienced acute respiratory failure necessitating orotracheal intubation. Following an extensive evaluation, the patient exhibited skin thickening, kidney failure, thrombocytopenia, microangiopathic anemia, and an antinuclear antibody with a nuclear fine speckled pattern at a titer of 1:320...
October 14, 2023: Rheumatology International
https://read.qxmd.com/read/37832064/coronavirus-disease-2019-associated-thrombotic-microangiopathy-treated-with-plasma-exchange-and-antihypertensive-therapy-in-a-patient-with-hiv-a-case-report-with-literature-review
#79
REVIEW
Eriko Masuda, Kazuaki Fukushima, Yu Hebisawa, Masayuki Tanaka, Akito Ohta, Akifumi Imamura
RATIONALE: Coronavirus disease 2019 (COVID-19) is an infectious disease that often causes complications in multiple organs and thrombosis due to abnormal blood coagulation. This case report aimed to describe the clinical course of COVID-19-associated thrombotic microangiopathy (TMA) and reviewed the comprehensive information on TMA, thrombotic thrombocytopenic purpura (TTP), and atypical hemolytic uremic syndrome associated with COVID-19 in the past literature. PATIENT CONCERNS: A 46-year-old Japanese man was diagnosed with human immunodeficiency virus infection 10 years ago and treated with antiretroviral therapy...
October 13, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/37827985/intravascular-volumes-and-the-influence-on-anemia-assessed-by-a-carbon-monoxide-rebreathing-method-in-patients-undergoing-maintenance-hemodialysis
#80
JOURNAL ARTICLE
Vårin Vinje, Tobias Bomholt, Carsten Lundby, Peter Oturai, Marianne Rix, Kristine Lindhard, Mads Hornum
INTRODUCTION: Fluid overload is a major challenge in hemodialysis patients and might cause hypervolemia. We speculated that hemodialysis patients reaching dry weight could have undetected hypervolemia and low hemoglobin (Hb) concentration (g/dL) due to hemodilution. METHODS: The study included hemodialysis patients (n = 22) and matched healthy controls (n = 22). Blood volume, plasma volume, red blood cell volume, and total Hb mass were determined using a carbon monoxide (CO)-rebreathing method in hemodialysis patients reaching dry weight and controls...
October 12, 2023: Hemodialysis International
keyword
keyword
160541
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.